Jonathan E. Rosenberg, MD, on Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

Posted: Friday, October 30, 2020

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses administering this combination regimen in patients with advanced disease.